Healio1d
Eosinophilic esophagitis improves with dupilumab regardless of food elimination diets
Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food ...
FiercePharma25d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...
Finanznachrichten13d
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...
Yahoo Finance13d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another ... including weight gain, high blood sugar, and mood changes. The FDA’s review is based on data ...
Bloomberg L.P.7d
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...
Yahoo Finance27d
Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars
Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...
Pharmabiz12d
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid
More than one million patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has ...
Seeking Alpha15d
Why Regeneron's Price May Soon Break Out
Regeneron Pharmaceuticals (NASDAQ ... The main reason is the extremely high competition in the PD-1/PD-L1 checkpoint inhibitors market, which includes Merck's Keytruda, Bristol-Myers Squibb's ...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Mena FN13d
Dupixent® (Dupilumab) Sbla Accepted For FDA Priority Review For The Targeted Treatment Of Bullous Pemphigoid (BP)
More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...
Medscape11d
Dupilumab Under FDA Priority Review for Bullous Pemphigoid
constipation, upper respiratory tract infection, limb injury, and insomnia, according to Sanofi. The dupilumab studies were funded by Sanofi and Regeneron, the companies co-developing dupilumab.